Spot Biosystems
↗Palo Alto, USA
Spot Biosystems is a biotechnology company focused on the development of mRNA-based therapeutics and extracellular vesicle (EV) research. The company utilizes proprietary research and development processes to create novel modalities for mRNA delivery, aiming to address unmet medical needs in areas such as rare diseases, cancer, and ischemic injury.
Originally commercializing research from The Ohio State University, the company operates as a platform developer. Their technology suite includes exosome-based liquid biopsy platforms for cancer detection and therapeutic intellectual property centered on gene therapy and high-precision mRNA delivery.
CLASSIFICATION
Company Type:Biotech
Therapeutic Areas:
Industry:Biotechnology
Sub-Industry:mRNA Therapeutics / Diagnostics
SIZE & FINANCIALS
Employees:1-50
Founded:2018
Ownership:private
Status:operating
FUNDING
Stage:Seed
Investors:LDV Partners, Shanda, LH Ventures
PIPELINE
Stage:Preclinical
Lead Drug Stage:Preclinical
Modalities:mRNA therapy, Extracellular vesicles
Active Trials:0
Trial Phases:-
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:The Ohio State University (Technology licensing)
COMPETITION
Position:Niche Player
LEADERSHIP
Key Executives:
Andrew Lee - Leadership
Scientific Founders:James Lee
LINKS
Website:spotbiosystems.com
⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Spot Biosystems and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Spot Biosystems. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.